When is Intravenous Iron Therapy Indicated?
Intravenous iron should be considered first-line treatment when hemoglobin is below 10 g/dL, in patients with active inflammatory conditions (especially IBD), when oral iron is not tolerated or has failed, when rapid iron repletion is needed, or in conditions where oral absorption is compromised.
Primary Indications for IV Iron
Absolute Indications
IV iron is the preferred route in the following scenarios 1, 2:
- Hemoglobin <10 g/dL - Oral iron is too slow and often ineffective at this severity
- Active inflammatory bowel disease - Inflammation blocks oral iron absorption and mobilization
- Previous intolerance to oral iron - Gastrointestinal side effects are common (up to 40% of patients)
- Oral iron failure - Ferritin levels fail to improve after adequate trial
- Need for erythropoiesis-stimulating agents (ESAs) - IV iron optimizes ESA response
Strong Indications by Clinical Context
Inflammatory Bowel Disease (IBD):
- Active disease with any degree of anemia 1, 3
- Hemoglobin 10-12 g/dL (women) or 10-13 g/dL (men) with inflammation 1
- Ferritin 30-100 μg/L with transferrin saturation <20% suggests combined iron deficiency and anemia of chronic disease 1
Chronic Heart Failure:
- Ferritin <100 μg/L OR transferrin saturation <20% 3
- Critical point: IV iron shows prognostic benefit in heart failure; oral iron does not 3
- Avoid oral iron due to gut edema impairing absorption 3
Chronic Kidney Disease:
- Predialysis or dialysis patients requiring ESA therapy 4, 5
- Functional iron deficiency (ferritin elevated but transferrin saturation <20%)
- Target ferritin 100-500 μg/L in hemodialysis patients 4
Perioperative Setting:
- Preoperative anemia correction when surgery is scheduled within 4-6 weeks 6
- Oral iron insufficient time to correct anemia before surgery
- Reduces transfusion requirements and complications 6
Post-Bariatric Surgery:
- Duodenal bypass disrupts normal iron absorption 2
- Oral iron often ineffective due to anatomical changes 3
Heavy Menstrual Bleeding:
- Ongoing blood loss exceeds oral iron replacement capacity 7, 8
- Moderate to severe anemia (Hb <100 g/L) 3
When Oral Iron May Be Appropriate
Oral iron can be considered ONLY when ALL of the following are present 1:
- Mild anemia (Hb 11.0-11.9 g/dL in women, 11.0-12.9 g/dL in men)
- Clinically inactive disease (no active inflammation)
- No previous intolerance to oral iron
- Adequate time for gradual correction (not urgent)
Dosing Considerations
Simplified dosing scheme (preferred over Ganzoni formula) 1:
| Hemoglobin (g/dL) | Body Weight <70 kg | Body Weight ≥70 kg |
|---|---|---|
| 10-12 (women) / 10-13 (men) | 1000 mg | 1500 mg |
| 7-10 | 1500 mg | 2000 mg |
Add 500 mg if hemoglobin <7 g/dL 1
Formulation Selection
Modern high-dose formulations allowing 1-2 infusions are strongly preferred 7, 2:
- Ferric carboxymaltose (FCM): 500-1000 mg per dose, 15-minute infusion
- Ferric derisomaltose (FDI): Up to 1500 mg (20 mg/kg), FDA-labeled for total dose infusion 7
- Iron isomaltoside 1000: 20 mg/kg with no ceiling, 1-hour infusion 9
Avoid iron dextran - requires test dose due to anaphylaxis risk 1
Safety Considerations
Common pitfall: Fear of adverse events leads to underutilization 10
- True anaphylaxis is very rare (<0.1%) 7, 2
- Most reactions are complement activation-related pseudo-allergy (infusion reactions), not true allergy 2
- Hypophosphatemia occurs in 50-74% with ferric carboxymaltose, can cause bone pain and fractures 11
- Monitor phosphate levels with FCM; consider alternative formulation if hypophosphatemia develops
Upper safety limits 1:
- Transferrin saturation >50%
- Ferritin >800 μg/L (general population)
- Ferritin >500 μg/L (hemodialysis patients) 4
Monitoring Response
Reassess 4-8 weeks after last infusion 7:
- Hemoglobin should increase 1-2 g/dL within 4 weeks 1
- Target ferritin ≥50 ng/mL (without inflammation) 7
- Do NOT check iron parameters within 4 weeks of infusion (circulating iron interferes with assays) 7
Critical Clinical Pearl
The most common error is underdosing IV iron 12. A recent audit showed mean estimated iron need was 1580 mg, but mean dose given was only 1244 mg, resulting in patients remaining anemic after >65% of treatment courses. Calculate total iron deficit and administer the full replacement dose rather than arbitrary smaller amounts.